Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.

Nanomedicine : nanotechnology, biology, and medicine - 1 Feb 2024

Kamath Divya, Iwakuma Tomoo, Bossmann Stefan H

Abstract excerpt

Among the tumor suppressor genes, TP53 is the most frequently mutated in human cancers, and most mutations are missense mutations causing production of mutant p53 (mutp53) proteins. TP53 mutations not only results in loss of function (LOH) as a transcription factor and a tumor suppressor, but also gain wild-type p53 (WTp53)-independent oncogenic functions that enhance cancer metastasis and progression (Yamamoto...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Mutation
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to RNA, Messenger

Share to Transcription Factors

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 38199451
DOI: 10.1016/j.nano.2024.102732
PMCID: PMC11108594

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.PMID 38199451Read ↗

Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.Semantic proximity Read ↗

Drugs Targeting p53 Mutations with FDA Approval and in Clinical TrialsSemantic proximity Read ↗

The Role of p53 in Nanoparticle-Based Therapy for CancerSemantic proximity Read ↗

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.Semantic proximity Read ↗

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy - Drug RepurposingSemantic proximity Read ↗

Will therapies that target tumour suppressor genes be useful in cancer treatment?Semantic proximity Read ↗

Targeting Oncogenic Mutant p53 for Cancer TherapySemantic proximity Read ↗

Side-Stepping the Guardian of the Genome: Current Cancer Therapeutics Targeting Mutant p53Semantic proximity Read ↗

Molecularly targeted therapies for p53-mutant cancers.Semantic proximity Read ↗

Reviving the guardian of the genome: Small molecule activators of p53.Semantic proximity Read ↗

Integrative Analysis of the Role of TP53 in Human Pan-CancerSemantic proximity Read ↗

Drugging p53 in cancer: one protein, many targets.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.